Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.
Checkpoint Therapeutics, Inc., listed under the ticker CKPT, is a pioneering immuno-oncology biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Founded in 2014 and headquartered in New York, New York, the company operates as a subsidiary of Fortress Biotech, Inc.
Checkpoint Therapeutics focuses on developing non-chemotherapy, immune-enhanced combination treatments. One of its leading product candidates is CK-101, currently in phase I clinical trials, aimed at treating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Another significant candidate is Cosibelimab, a programmed death ligand-1 (PD-L1) inhibitor in phase I trials for selected recurrent or metastatic cancers.
In addition to these, Checkpoint Therapeutics is working on CK-103, a small molecule inhibitor targeting BET bromodomains, and CK-302, a human agonistic antibody designed for oncology indications. The company has also developed a strong portfolio of antibodies focusing on PD-L1, GITR, and CAIX targets.
Checkpoint Therapeutics collaborates with TG Therapeutics, Inc. to develop and commercialize specific assets in hematological malignancies. This partnership underscores the company's commitment to advancing cancer therapies through strategic alliances.
Checkpoint Therapeutics' robust pipeline, innovative approaches to cancer treatment, and strategic collaborations make it a significant player in the biopharmaceutical industry. Investors and stakeholders can look forward to the company's continuous advancements and contributions to oncology.
Checkpoint Therapeutics (CKPT) has launched the CONTERNO study, a global Phase 3 trial assessing cosibelimab combined with chemotherapy for treating non-squamous non-small cell lung cancer (NSCLC). The trial aims to enhance overall survival in patients and support worldwide regulatory approvals. With 1.7 million new NSCLC cases reported in 2020, the study focuses on potentially improving patient outcomes. The primary endpoint is overall survival, while key secondary endpoints include progression-free survival and safety, involving approximately 560 subjects.
Checkpoint Therapeutics (NASDAQ: CKPT) announced its third-quarter financial results for 2021, highlighting a net loss of $11.3 million, or $0.14 per share, compared to a loss of $4.9 million, or $0.09 per share in Q3 2020. R&D expenses surged to $9.4 million, up from $2.5 million in the prior year, primarily due to costs associated with cosibelimab trials. Cash reserves decreased to $60.2 million, down $4.9 million from the previous quarter. The company aims for a Biologics License Application for cosibelimab next year and is advancing a Phase 3 trial for non-small cell lung cancer.
Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021, at 9:20 a.m. ET. The company’s management will also hold one-on-one meetings during the event. A live webcast of the chat will be available on Checkpoint's website for 30 days post-event. Checkpoint focuses on developing immunotherapy and targeted oncology treatments, including its lead antibody candidate, cosibelimab, currently undergoing a Phase 1 clinical trial.
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) announces participation of CEO James Oliviero in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, available on-demand at 7 a.m. ET. The second is Lake Street’s 5th Annual Best Ideas Growth Conference on September 15, 2021, featuring one-on-one meetings only. Checkpoint, focused on immunotherapy for solid tumors, is evaluating its lead candidates, including cosibelimab and CK-101.
Checkpoint Therapeutics (CKPT) reported its Q2 2021 financial results, highlighting key advancements in its clinical pipeline. The company completed patient enrollment for its pivotal trial of cosibelimab, an anti-PD-L1 antibody, and expects top-line data by Q4 2021, aiming for a BLA submission in 2022. Checkpoint's cash position improved to $65.1 million, up from $60 million in Q1. However, R&D expenses rose significantly to $7.2 million, contributing to a net loss of $9.1 million, or $0.12 per share, compared to $4.6 million, or $0.09 per share, in Q2 2020.
Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will speak at the Ladenburg Thalmann 2021 Healthcare Conference on July 13-14, 2021. The company will present a corporate update on July 14 at 11:30 a.m. ET and engage in one-on-one meetings. A webcast of the presentation will be available for 30 days on their investor website. Checkpoint focuses on developing novel cancer treatments, notably its lead product cosibelimab, an anti-PD-L1 antibody, and CK-101, an EGFR inhibitor for lung cancer. For more details, visit www.checkpointtx.com.
Checkpoint Therapeutics, Inc. (CKPT) announced the completion of patient enrollment in its registration-enabling clinical trial for cosibelimab targeting metastatic cutaneous squamous cell carcinoma (cSCC). Top-line results are anticipated in 4Q 2021, with a Biologics License Application (BLA) submission planned for 1H 2022. Cosibelimab aims to disrupt the $25 billion PD-(L)1 market with competitive pricing and a favorable safety profile, aiming for rapid market adoption. The company also expects to include data on locally advanced cSCC in its upcoming submissions.
Checkpoint Therapeutics (NASDAQ: CKPT) reported its Q1 2021 financial results, highlighting advancements in drug development and a strengthened cash position. Cash and cash equivalents increased to $60 million, up from $40.8 million at year-end 2020. R&D expenses rose to $4.2 million, while G&A expenses climbed to $2.4 million. The net loss for Q1 2021 was $6.5 million, or $0.09 per share, compared to a loss of $3.3 million, or $0.06 per share, in Q1 2020. Enrollment in a pivotal study for cosibelimab is nearing completion, with results expected by year-end.
Checkpoint Therapeutics (NASDAQ: CKPT) reported its 2020 financial results, highlighting a net loss of $23.1 million, down from $24.7 million in 2019. As of December 31, 2020, the company had $40.8 million in cash, up from $26.1 million a year prior. Significant progress was made on cosibelimab, with a 90% enrollment in its registration-enabling study for metastatic cutaneous squamous cell carcinoma (mCSCC) and a promising objective response rate of 51.4%. The company anticipates full top-line results in Q2 2021 and aims for a BLA submission to the FDA in 2022.
Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The session will be available on-demand starting March 9, 2021, at 7:00 a.m. ET on Checkpoint's website for about 30 days.
The company is focused on developing immunotherapy treatments for solid tumors, notably evaluating cosibelimab, a novel anti-PD-L1 antibody, and CK-101, a targeted EGFR inhibitor for lung cancer.
FAQ
What is the current stock price of Checkpoint Therapeutics (CKPT)?
What is the market cap of Checkpoint Therapeutics (CKPT)?
What does Checkpoint Therapeutics, Inc. specialize in?
What are the key products in Checkpoint Therapeutics' pipeline?
Where is Checkpoint Therapeutics headquartered?
When was Checkpoint Therapeutics founded?
What strategic partnerships does Checkpoint Therapeutics have?
What is Cosibelimab?
What stage is CK-101 in?
Who is the parent company of Checkpoint Therapeutics?
What types of cancers is Checkpoint Therapeutics focusing on?
Does Checkpoint Therapeutics have any small molecule inhibitors in development?
